Publications — Radcliffe Department of Medicine

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Diabetes Technology Society Error Grid and Trend Accuracy Matrix for Glucose Monitors.

Klonoff DC. et al, (2024), J Diabetes Sci Technol

Going beyond randomised controlled trials to assess treatment effect heterogeneity across target populations.

Lugo-Palacios DG. et al, (2024), Health Econ

Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial.

Schilling WHK. et al, (2024), PLoS Med, 21

Examining the impact of structural uncertainty across ten type 2 diabetes models: Results from the 2022 Mount Hood Challenge.

Altunkaya J. et al, (2024), Value Health

Protocol for a double-blind placebo-controlled randomised controlled trial assessing the impact of oral semaglutide in amyloid positivity (ISAP) in community dwelling UK adults.

Koychev I. et al, (2024), BMJ Open, 14

Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91).

Adler AI. et al, (2024), Lancet

Comparative effectiveness of second line oral antidiabetic treatments among people with type 2 diabetes mellitus: emulation of a target trial using routinely collected health data.

Bidulka P. et al, (2024), BMJ, 385

Overcoming challenges in the economic evaluation of interventions to optimise antibiotic use

ROOPE L. et al, (2024), Communications Medicine

ASCEND-Eye: Effects of Omega-3 Fatty Acids on Diabetic Retinopathy.

Sammons EL. et al, (2024), Ophthalmology, 131, 526 - 533

ASCEND-Eye: Effects of Aspirin on Diabetic Retinopathy.

Sammons EL. et al, (2024), Ophthalmology

12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study

De Giorgi R. et al, (2024), eClinicalMedicine

Diabetes mellitus in Kabuki syndrome 1 on a background of post-transplant diabetes mellitus.

Chew Sue Mei S. et al, (2024), Endocrinology, diabetes & metabolism case reports, 2024, 23 - 133

Live to eat and eat to live longer.

Adler A. and Saksena R., (2023), Nat Food

Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial.

Hundertmark MJ. et al, (2023), Circulation, 147, 1654 - 1669

Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease.

Bethel MA. et al, (2023), Cardiovasc Diabetol, 22

Teplizumab approval for type 1 diabetes in the USA.

Beran D. et al, (2023), Lancet Diabetes Endocrinol, 11, 78 - 80

What, Where, and How to Collect Real-World Data and Generate Real-World Evidence to Support Drug Reimbursement Decision-Making in Asia: A reflection Into the Past and A Way Forward

Kc S. et al, (2023), International Journal of Health Policy and Management, 12

Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes - Authors' reply.

Nazarzadeh M. et al, (2022), Lancet Diabetes Endocrinol, 10, 841 - 842

New ways of evaluating and purchasing antimicrobials.

Adler A. et al, (2022), Lancet Infect Dis, 22

Calibrating a network meta-analysis of diabetes trials of sodium glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor analogues and dipeptidyl peptidase-4 inhibitors to a representative routine population: a systematic review protocol.

Butterly E. et al, (2022), BMJ Open, 12

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?